Occidental Asset Management LLC Buys New Shares in TG Therapeutics, Inc. $TGTX

Posted by Stanley Muller on Aug 18th, 2026

Occidental Asset Management LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 12,040 shares of the biopharmaceutical company’s stock, valued at approximately $661,000.

Several other large investors have also made changes to their positions in the business. Danske Bank A S bought a new stake in TG Therapeutics in the 3rd quarter valued at $25,000. EverSource Wealth Advisors LLC boosted its holdings in shares of TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 365 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 560 shares during the last quarter. Truvestments Capital LLC grew its position in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,026 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of TG Therapeutics during the fourth quarter valued at about $52,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $49.28 on Tuesday. The firm’s fifty day simple moving average is $52.64 and its two-hundred day simple moving average is $40.37. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $59.30. The firm has a market capitalization of $7.54 billion, a P/E ratio of 17.99, a P/E/G ratio of 2.09 and a beta of 1.62.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.26). The business had revenue of $240.34 million for the quarter, compared to analysts’ expectations of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business’s revenue for the quarter was up 70.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.17 EPS. Analysts forecast that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TGTX shares. Bank of America increased their target price on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Jefferies Financial Group reissued a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a research report on Monday, June 22nd. Finally, JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $63.00.

Check Out Our Latest Report on TG Therapeutics

About TG Therapeutics

(Free Report)

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.